EDNRA and pulmonary arterial hypertension: The ETA receptor antagonism is pivotal in hypertension treatment. Due to its pathophysiology, both ETA and ETB receptor blocking is necessary for PAH treatment, so dual ERA, like Macitentan, might be the appropriate drug for PAH treatment [15].